Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®.....»»

Boehringer Ingelheim's adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study.....»»

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin®.....»»

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations.....»»

Boehringer Ingelheim Phase III study now enrolling patients with progressive fibrosing lung diseases.....»»

Boehringer Ingelheim biosimilar candidate to Humira® accepted for EMA and FDA regulatory review.....»»

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 2016.....»»

New Data: Spiolto® Respimat® significantly improves exercise capacity in people with COPD.....»»

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma.....»»

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Sun Pharma Announces Positive Topline Results of Confirmatory Phase-3 Clinical Trial for Seciera(TM) for Treatment of Dry Eye.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon's Proposed Biosimilar Trastuzumab Phase 3 Data.....»»

Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung cancer patients tested for EGFR mutations at risk of missing out on personalised treatments for their disease.....»»

Suven Life gets patents in Europe, Israel for neuro-degenerative drug candidate.....»»